Mastering interventional pharmacotherapy for ACS

With an unrestricted educational grant from THE MEDICINES COMPANY

Chairpersons: A. Baumbach, P.G. Steg

Learning Objectives

  • To review the impact of pharmacological agents on clinical outcomes, especially in ACS
  • To discuss thrombin inhibition in relation to efficacy and safety, and mortality reduction
  • To review changing treatment paradigms of acute versus chronic pharmacotherapy in patients undergoing PCI and discuss the role of new agents in today's practice

Presentations available when logged in:

  • Introduction and objectives
  • Acute versus chronic antithrombotic management in ACS: need for a paradigm shift?
  • Antithrombotic targets for treating ACS patients
  • Pharmacology in high-risk PCI: focus on clinical outcomes
  • Bringing is all together: making the best choices for the patient and the system